Park West Asset Management LLC Anavex Life Sciences Corp. Transaction History

Park West Asset Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$2.38 - $5.81 $8.02 Million - $19.6 Million	-3,370,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$2.31 - $3.14 $277,200 - $376,800	120,000 Added 3.69%	3,370,000 $8.73 Million
Q3 2019 Nov 14, 2019	BUY	$2.22 - $3.9 $555,000 - $975,000	250,000 Added 8.33%	3,250,000 $10.3 Million
Q2 2019 Aug 14, 2019	SELL	$2.75 - $3.7 $1.36 Million - $1.83 Million	-495,615 Reduced 14.18%	3,000,000 $10.1 Million
Q4 2018 Feb 14, 2019	BUY	$1.25 - $2.75 $66,812 - $146,987	53,450 Added 1.55%	3,495,615 $5.45 Million
Q3 2018 Nov 14, 2018	BUY	$2.23 - $3.82 $1.12 Million - $1.91 Million	500,000 Added 16.99%	3,442,165 $9.4 Million
Q2 2018 Aug 14, 2018	SELL	$2.08 - $4.26 $150,176 - $307,572	-72,200 Reduced 2.4%	2,942,165 $7.71 Million
Q1 2018 May 15, 2018	BUY	$2.32 - $3.44 $699,496 - $1.04 Million	301,507 Added 11.11%	3,014,365 $8.32 Million
Q4 2017 Feb 14, 2018	SELL	$3.12 - $4.94 $501,390 - $793,867	-160,702 Reduced 5.59%	2,712,858 $8.74 Million
Q3 2017 Nov 14, 2017	BUY	$3.42 - $4.87 $9.83 Million - $14 Million	2,873,560	2,873,560 $11.9 Million

163

27.5M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $673M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Park West Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Park West Asset Management LLC with notifications on news.